AR133828A1 - ANTI-TDP-43 ANTIBODIES AND THEIR USES - Google Patents
ANTI-TDP-43 ANTIBODIES AND THEIR USESInfo
- Publication number
- AR133828A1 AR133828A1 ARP240102461A ARP240102461A AR133828A1 AR 133828 A1 AR133828 A1 AR 133828A1 AR P240102461 A ARP240102461 A AR P240102461A AR P240102461 A ARP240102461 A AR P240102461A AR 133828 A1 AR133828 A1 AR 133828A1
- Authority
- AR
- Argentina
- Prior art keywords
- variable domain
- chain variable
- seq
- antibody
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación proporciona anticuerpos que se unen específicamente al TDP-43 humano y métodos de uso de estos anticuerpos para tratar a pacientes con enfermedades relacionadas con el TDP-43, incluida la esclerosis lateral amiotrófica (ELA). Reivindicación 1: Un anticuerpo monoclonal aislado que compite por la unión a la proteína de unión al ADN de respuesta transactiva de 43 kD (TDP-43) con: un anticuerpo que comprende un dominio variable de cadena pesada de SEQ ID Nº 1 y un dominio variable de cadena ligera de SEQ ID Nº 24; un anticuerpo que comprende un dominio variable de cadena pesada de SEQ ID Nº 63 y un dominio variable de cadena ligera de SEQ ID Nº 65; un anticuerpo que comprende un dominio variable de cadena pesada de SEQ ID Nº 67 y un dominio variable de cadena ligera de SEQ ID Nº 69; un anticuerpo que comprende un dominio variable de cadena pesada de SEQ ID Nº 71 y un dominio variable de cadena ligera de SEQ ID Nº 73; un anticuerpo que comprende un dominio variable de cadena pesada de SEQ ID Nº 75 y un dominio variable de cadena ligera de SEQ ID Nº 77; o un anticuerpo que comprende un dominio variable de cadena pesada de SEQ ID Nº 79 y un dominio variable de cadena ligera de SEQ ID Nº 81. Reivindicación 3: Un anticuerpo que se une específicamente a TDP-43, que comprende tres CDR de cadena ligera y tres CDR de cadena pesada de un anticuerpo de ratón caracterizado por un dominio variable de cadena pesada que comprende la SEQ ID Nº 1 y un dominio variable de cadena ligera que comprende la SEQ ID Nº 24. Reivindicación 94: Una composición farmacéutica que comprende un anticuerpo de cualquiera de las reivindicaciones 1 - 93 y un portador farmacéuticamente aceptable. Reivindicación 95: Un ácido nucleico que codifica el dominio variable de cadena pesada y/o el dominio variable de cadena ligera de un anticuerpo de cualquiera de las reivindicaciones 1 - 93. Reivindicación 96: Un vector que comprende un ácido nucleico que codifica un dominio variable de cadena pesada maduro y un dominio variable de cadena ligera unido operativamente a una o más secuencias reguladoras para efectuar la expresión en una célula de mamífero de un anticuerpo de cualquiera de las reivindicaciones 1 - 93. Reivindicación 99: Una célula hospedadora transformada con el vector de cualquiera de las reivindicaciones 96 - 98. Reivindicación 100: Una célula hospedadora que comprende el ácido nucleico de la reivindicación 95.This disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including amyotrophic lateral sclerosis (ALS). Claim 1: An isolated monoclonal antibody that competes for binding to the 43 kD transactive response DNA-binding protein (TDP-43) with: an antibody comprising a heavy chain variable domain of SEQ ID No. 1 and a light chain variable domain of SEQ ID No. 24; an antibody comprising a heavy chain variable domain of SEQ ID No. 63 and a light chain variable domain of SEQ ID No. 65; an antibody comprising a heavy chain variable domain of SEQ ID No. 67 and a light chain variable domain of SEQ ID No. 69; an antibody comprising a heavy chain variable domain of SEQ ID No. 71 and a light chain variable domain of SEQ ID No. 73; an antibody comprising a heavy chain variable domain of SEQ ID No. 75 and a light chain variable domain of SEQ ID No. 77; or an antibody comprising a heavy chain variable domain of SEQ ID No. 79 and a light chain variable domain of SEQ ID No. 81. Claim 3: An antibody specifically binding to TDP-43, comprising three light chain CDRs and three heavy chain CDRs of a mouse antibody characterized by a heavy chain variable domain comprising SEQ ID No. 1 and a light chain variable domain comprising SEQ ID No. 24. Claim 94: A pharmaceutical composition comprising an antibody of any of claims 1-93 and a pharmaceutically acceptable carrier. Claim 95: A nucleic acid encoding the heavy chain variable domain and/or the light chain variable domain of an antibody of any of claims 1-93. Claim 96: A vector comprising a nucleic acid encoding a mature heavy chain variable domain and a light chain variable domain operatively linked to one or more regulatory sequences to effect expression in a mammalian cell of an antibody of any of claims 1-93. Claim 99: A host cell transformed with the vector of any of claims 96-98. Claim 100: A host cell comprising the nucleic acid of claim 95.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363538595P | 2023-09-15 | 2023-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133828A1 true AR133828A1 (en) | 2025-11-05 |
Family
ID=92932943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240102461A AR133828A1 (en) | 2023-09-15 | 2024-09-13 | ANTI-TDP-43 ANTIBODIES AND THEIR USES |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR133828A1 (en) |
| TW (1) | TW202530253A (en) |
| WO (1) | WO2025059486A1 (en) |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DE19539493A1 (en) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Strong homologous promoter from hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| DE60036082T2 (en) | 1999-02-05 | 2008-06-12 | Samsung Electronics Co., Ltd., Suwon | METHOD AND DEVICE FOR RECONSTRUCTING TEXTURE IMAGES |
| PE20020574A1 (en) | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| JP4344325B2 (en) | 2002-11-29 | 2009-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Novel neomycin phosphotransferase gene and method for selecting highly producing recombinant cells |
| DE10338531A1 (en) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for recloning production cells |
| CA2578400C (en) | 2004-11-10 | 2014-01-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| PT2099823E (en) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Variant target binding agents and uses thereof |
| PT2126093E (en) | 2007-03-02 | 2012-12-03 | Boehringer Ingelheim Pharma | Improvement of protein production |
| EP2189526B1 (en) * | 2007-07-06 | 2013-09-04 | Tokyo Metropolitan Institute of Medical Science | Antibody binding specifically to tdp-43 aggregate |
| EP2031064A1 (en) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Method for increasing protein titres |
| SG11201401735WA (en) * | 2011-10-28 | 2014-05-29 | Biogen Idec Internat Neuroscience Gmbh | Tdp-43 specific binding molecules |
-
2024
- 2024-09-13 WO PCT/US2024/046651 patent/WO2025059486A1/en active Pending
- 2024-09-13 AR ARP240102461A patent/AR133828A1/en unknown
- 2024-09-13 TW TW113134924A patent/TW202530253A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202530253A (en) | 2025-08-01 |
| WO2025059486A1 (en) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992755A1 (en) | NEW MONOCLONAL ANTIBODIES FOR PROTEIN 4 ASSOCIATED WITH CYTOTOXIC T-Lymphocytes, (CTLA-4) | |
| AR132614A2 (en) | Anti-CCR8 antibodies and their uses | |
| AR126019A1 (en) | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES | |
| AR111203A1 (en) | IMMUNOCATE PLAYERS | |
| AR045056A1 (en) | ANTI-NGF ANTIBODIES NEUTRALIZING HUMANS AS SELECTIVE INHIBITORS OF THE NGF ROAD | |
| PE20250416A1 (en) | COMPOSITIONS AND METHODS OF MASP-3 INHIBITION FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS | |
| AR109264A1 (en) | UNION PROTEINS SIMILAR TO BIESPECTIFIC ANTIBODY THAT SPECIFICALLY JOIN CD3 AND CD123 | |
| AR110017A1 (en) | PD-1 ANTIBODIES AND USES OF THESE | |
| PE20181089A1 (en) | HUMAN ANTI-CD19 ANTIBODIES WITH HIGH AFFINITY | |
| AR095614A1 (en) | BISPS SPECIFIC HETERODIMERIC ANTIBODIES | |
| AR116526A1 (en) | ANTI-HLA-G ANTIBODIES, COMPOSITIONS INCLUDING ANTI-HLA-G ANTIBODIES AND METHODS OF USE OF ANTI-HLA-G ANTIBODIES | |
| PE20241623A1 (en) | OPTIMIZATION OF ANTIBODIES THAT BIND TO LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) AND THEIR USES | |
| PE20110225A1 (en) | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C5 | |
| AR104213A1 (en) | ANTI-BODIES ANTI-CD38 AS THERAPEUTIC AGENTS | |
| MX369276B (en) | AGENTS FOR THE TREATMENT OF CANCER DISEASES THAT EXPRESS CLAUDIN. | |
| UA99701C2 (en) | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY Binds TO LIGAND-1 PROGRAMMED CELL DAMAGE (PD-L1) | |
| EA200970477A1 (en) | HUMAN MONOCLONAL ANTIBODIES TO BTLA AND METHODS OF APPLICATION | |
| AR072039A1 (en) | ANTIBODIES AGAINST THE VIRUS OF HEPATITIS C | |
| AR040046A1 (en) | ANTI-IGFR HUMAN NEUTRALIZING ANTIBODY | |
| Yang et al. | Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies | |
| AR109533A2 (en) | ANTI-FRACTALKINA ANTIBODIES OR A FRAGMENT OF UNION TO THE FKN OF THIS, COMPOSITIONS THAT INCLUDE IT AND METHODS TO TREAT INFLAMMATORY DISORDERS | |
| BR112022019129A2 (en) | SIGLEC15 BINDING ANTIBODIES AND USES THEREOF | |
| PE20211742A1 (en) | CD200R AGONIST ANTIBODIES AND THEIR USES | |
| AR127271A1 (en) | BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND CD20, AND USES THEREOF | |
| AR124084A1 (en) | HEAVY CHAIN ANTIBODIES THAT BIND THE α-FOLATE RECEPTOR |